Boston Scientific's Obsidio embolic occluded all target vessels in 125-patient U.S. registry
Boston Scientific's Obsidio embolic occluded 100% of target vessels in the 125-patient OCCLUDE registry; the FDA approves Infilbray for type 3 Gaucher disease and Livsayis, the first siRNA therapy for myasthenia gravis.